Cargando…

Met in Urological Cancers

Met is a tyrosine kinase receptor that is considered to be a proto-oncogene. The hepatocyte growth factor (HGF)-Met signaling system plays an important role in tumor growth, invasion, and metastasis in many types of malignancies. Furthermore, Met expression has been reported to be a useful predictiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyata, Yasuyoshi, Asai, Akihiro, Mitsunari, Kensuke, Matsuo, Tomohiro, Ohba, Kojiro, Mochizuki, Yasushi, Sakai, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276973/
https://www.ncbi.nlm.nih.gov/pubmed/25521854
http://dx.doi.org/10.3390/cancers6042387
_version_ 1782350328780292096
author Miyata, Yasuyoshi
Asai, Akihiro
Mitsunari, Kensuke
Matsuo, Tomohiro
Ohba, Kojiro
Mochizuki, Yasushi
Sakai, Hideki
author_facet Miyata, Yasuyoshi
Asai, Akihiro
Mitsunari, Kensuke
Matsuo, Tomohiro
Ohba, Kojiro
Mochizuki, Yasushi
Sakai, Hideki
author_sort Miyata, Yasuyoshi
collection PubMed
description Met is a tyrosine kinase receptor that is considered to be a proto-oncogene. The hepatocyte growth factor (HGF)-Met signaling system plays an important role in tumor growth, invasion, and metastasis in many types of malignancies. Furthermore, Met expression has been reported to be a useful predictive biomarker for disease progression and patient survival in these malignancies. Many studies have focused on the clinical significance and prognostic role of Met in urological cancers, including prostate cancer (PCa), renal cell carcinoma (RCC), and urothelial cancer. Several preclinical studies and clinical trials are in progress. In this review, the current understanding of the pathological role of Met in cancer cell lines, its clinical significance in cancer tissues, and its predictive value in patients with urological cancers are summarized. In particular, Met-related malignant behavior in castration-resistant PCa and the different pathological roles Met plays in papillary RCC and other histological types of RCC are the subjects of focus. In addition, the pathological significance of phosphorylated Met in these cancers is shown. In recent years, Met has been recognized as a potential therapeutic target in various types of cancer; therapeutic strategies used by Met-targeted agents in urological cancers are summarized in this review.
format Online
Article
Text
id pubmed-4276973
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-42769732015-01-15 Met in Urological Cancers Miyata, Yasuyoshi Asai, Akihiro Mitsunari, Kensuke Matsuo, Tomohiro Ohba, Kojiro Mochizuki, Yasushi Sakai, Hideki Cancers (Basel) Review Met is a tyrosine kinase receptor that is considered to be a proto-oncogene. The hepatocyte growth factor (HGF)-Met signaling system plays an important role in tumor growth, invasion, and metastasis in many types of malignancies. Furthermore, Met expression has been reported to be a useful predictive biomarker for disease progression and patient survival in these malignancies. Many studies have focused on the clinical significance and prognostic role of Met in urological cancers, including prostate cancer (PCa), renal cell carcinoma (RCC), and urothelial cancer. Several preclinical studies and clinical trials are in progress. In this review, the current understanding of the pathological role of Met in cancer cell lines, its clinical significance in cancer tissues, and its predictive value in patients with urological cancers are summarized. In particular, Met-related malignant behavior in castration-resistant PCa and the different pathological roles Met plays in papillary RCC and other histological types of RCC are the subjects of focus. In addition, the pathological significance of phosphorylated Met in these cancers is shown. In recent years, Met has been recognized as a potential therapeutic target in various types of cancer; therapeutic strategies used by Met-targeted agents in urological cancers are summarized in this review. MDPI 2014-12-16 /pmc/articles/PMC4276973/ /pubmed/25521854 http://dx.doi.org/10.3390/cancers6042387 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Miyata, Yasuyoshi
Asai, Akihiro
Mitsunari, Kensuke
Matsuo, Tomohiro
Ohba, Kojiro
Mochizuki, Yasushi
Sakai, Hideki
Met in Urological Cancers
title Met in Urological Cancers
title_full Met in Urological Cancers
title_fullStr Met in Urological Cancers
title_full_unstemmed Met in Urological Cancers
title_short Met in Urological Cancers
title_sort met in urological cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276973/
https://www.ncbi.nlm.nih.gov/pubmed/25521854
http://dx.doi.org/10.3390/cancers6042387
work_keys_str_mv AT miyatayasuyoshi metinurologicalcancers
AT asaiakihiro metinurologicalcancers
AT mitsunarikensuke metinurologicalcancers
AT matsuotomohiro metinurologicalcancers
AT ohbakojiro metinurologicalcancers
AT mochizukiyasushi metinurologicalcancers
AT sakaihideki metinurologicalcancers